GlobeNewswire

Kinnevik: Extraordinary General Meeting 2019

Share

Kinnevik AB (publ) ("Kinnevik") today held an Extraordinary General Meeting (the "EGM"). The EGM resolved in accordance with the Board's proposal regarding distribution of Kinnevik's holding in Millicom International Cellular S.A. ("Millicom") to its shareholders through a share redemption plan.

The EGM resolved to distribute Kinnevik's holding in Millicom (in the form of Swedish depositary receipts ("SDRs") in Millicom listed on Nasdaq Stockholm and convertible into Millicom shares listed on Nasdaq New York), to holders of ordinary shares (i.e. holders of Class A shares and Class B shares) in Kinnevik, through a share redemption plan. Each ordinary share in Kinnevik (irrespective of share class) will entitle to one (1) redemption share, and each redemption share will entitle to 0.1372 Millicom SDRs, corresponding to a value transfer of SEK 59 per ordinary share in Kinnevik (based on the closing price of Millicom SDRs on Nasdaq Stockholm as at 6 November 2019).

The EGM authorised the Board to set the record dates for the right to receive redemption shares, for the redemption of these, and for the right to receive Millicom SDRs. The Board has set the record date for the share split and the right to receive redemption shares to 14 November 2019 (i.e. the same date as stated in the notice and the information material regarding the share redemption plan). The last trading day in the Kinnevik share before the share split including the right to receive redemption shares is 12 November 2019. From and including 13 November 2019, the Kinnevik share will be traded not including the right to receive redemption shares.

The redemption shares will be traded on Nasdaq Stockholm from and including 15 November 2019 to and including 29 November 2019. The redemption consideration, in the form of Millicom SDRs, will be paid out to holders of redemption shares on 3 December 2019 and will be available on securities accounts/nominee accounts or equivalent on 5 December 2019. Kinnevik will arrange for fractions of Millicom SDRs to be sold on behalf of the shareholders, and payment of the proceeds from this sale is estimated to be available to such shareholders around 16 December 2019.

For more information regarding the distribution of Kinnevik's holding in Millicom, please refer to Kinnevik's website www.kinnevik.com under the heading "General Meetings" (which can be found under the section "Governance") where i.e. an information brochure regarding the distribution of Kinnevik's Millicom SDRs and the share redemption plan is available.

For further information, visit www.kinnevik.com or contact:

Torun Litzén, Director Investor Relations
Phone +46 (0)70 762 00 50
Email press@kinnevik.com

Kinnevik is an industry focused investment company with an entrepreneurial spirit. Our purpose is to build digital businesses that provide more and better choice. We do this by working in partnership with talented founders and management teams to create, develop and invest in fast growing businesses in developed and emerging markets. We believe in delivering both shareholder and social value by building companies that contribute positively to society. Kinnevik was founded in 1936 by the Stenbeck, Klingspor and von Horn families. Kinnevik’s shares are listed on Nasdaq Stockholm’s list for large cap companies under the ticker codes KINV A and KINV B.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Úlfar Freyr Stefánsson appointed Chief Risk Officer of Arion Bank – Gísli S. Óttarsson leaves the Bank25.5.2020 18:50:52 CESTPress release

Úlfar Freyr Stefánsson has been appointed Chief Risk Officer of Arion Bank. Úlfar is taking over from Gísli S. Óttarsson who will be leaving the Bank after having been Chief Risk Officer and a member of the Bank’s executive committee since 2009. Gísli will step down at the end of the month but will continue to work in an advisory capacity for the Bank. Úlfar joined the Bank’s Risk Management division in 2013 after having worked at Kaupthing since 2010, where his positions included head of risk management. Úlfar was Head of Portfolio Risk at Arion Bank from 2013 to 2015, when he took over as Head of Balance Sheet Risk. Úlfar has a doctorate in mathematics from Georgia Institute of Technology and a master’s from the same institution. He also has a BSc in mathematics from the University of Iceland and is a certified securities broker. Benedikt Gíslason, CEO of Arion Bank: “I would like to thank Gísli for his excellent work and vital contribution to the Bank over the years. His successor a

PRESS RELEASE: NACON: 2019/20 ANNUAL RESULTS25.5.2020 18:34:13 CESTPress release

Press release Lesquin, 25 May 2020, 18 :00 hrs Strong growth of profitability in 2019/20: ·Current Operating Profit: 22,6 M€ (+80,3%) ·Net Résult: 15,3 M€ (+41,8%) Outlook 2020/21 : ·Sales between 140 and 150 M€ ·Current Operating Profit Rate: 18% NACON (ISIN FR0013482791) today releases its audited consolidated results for the financial year closing on 31 March 2020 as approved by its Board of directors on 25 May 2020. Consolidated in M€ IFRS03/2020 (4)03/2019 (3) Var.Sales129.4113.1+14.4%Gross margin (1) In % of Sales EBITDA (2) In % of Sales 79.1 61.1% 48.4 37.4% 62.4 55.2% 33.4 29.5%+26.7% +45.0%Result from current operations In % of Sales Non recurrent items (including Bonus Shares)22.6 17.5% (2.0)12.5 11.1% 0.8 +80.3% Operating result In % of Sales20.6 15.9%13.4 11.8%+53.8%Financial result Including currency gain (loss)(0.6)(0.4) Earnings before tax In % of Sales20.0 15.4%13.0 11.5%+53.6%Tax(4.7)(2.2)Net result for the period In % of Sales15.3 11.8%10.8 9.5% +41.8% (1) Gross marg

PRESS RELEASE: BIGBEN: 2019/20 Annual Résults25.5.2020 18:15:16 CESTPress release

Press release Lesquin, 25 May 2020 18:00 2019/20 Annual Résults: ·Sales: 263.5 M€ (+7.3%) ·Current Operating Income: 23.7 M€ (+9.0%) ·Net Résult: 16.2 M€ (-6.3%) New « BIGBEN 2023 » plan: ·2022/23 sales: 350 M€ ·2022/23 Current Operating Income Rate: 13% BIGBEN INTERACTIVE (ISIN FR0000074072) today releases its audited consolidated results for the financial year closing on 31 March 2020 as approved by its Board of directors on 25 May 2020. Consolidated in M€ IFRS03/202003/2019 Change.Sales263.5245.5+7.3%Gross margin (1) In % of Sales EBITDA (2) In % of Sales 108.9 41,3% 52.5 19.9% 97.6 39.8% 44.9 18.3%+11.6% +16.8%Result from current operations In % of Sales Non recurrent items (including Bonus Shares)23.7 9.0% (2.9)21.7 8.9% 0.6 +9.0% Operating result In % of Sales20.8 7.9%22.3 9.1%-6.7%Financial result Including currency gain (loss)(1.1) 0.30.5 1.5 Earnings before tax In % of Sales19.7 7.5%22.8 9.3%-13.3%Tax(3.5)(5.4)Net result for the period In % of Sales16.2 6.2%17.3 7.1% -6.3% Of

Inventiva secures a new patent for lanifibranor in China expanding the protection of its lead product candidate25.5.2020 17:45:00 CESTPress release

New patent granted by the CNIPA is directed at the use of lanifibranor for the treatment of several fibrotic diseases, including NASH, and expires in June 2035 The patent expands the existing patent portfolio for lanifibranor in the world’s second largest pharmaceutical market1 Daix (France), May 25, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the China National Intellectual Property Administration (CNIPA) granted a new patent directed at the use of lanifibranor for the treatment of several fibrotic diseases in China until June 2035. This new patent covers, among others, the use of the Company’s lead product candidate lanifibranor for the treatment of NASH, hepatic fibrosis, chronic renal failure and fibrotic pulmonary disorder. It thereby expands the

CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER25.5.2020 16:20:00 CESTPress release

Bid procedure on 27 May 2020 Certificate: Commercial paper issued in SEK by non-financial companies with a registered office in Sweden and with a remaining maturity of up to six months on the Bid date, i.e. with the maturity date on 27 November 2020 at the latest. Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after 18 May 2020. Bids: Counterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se. Bid date: Wednesday 27 May 2020 Bid time: 0900-0930 hours (CEST) on the Bid date Requested volume: (corresponding nominal amount) SEK 4 billion Highest permitted bid volume: (corresponding nominal amount) The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in e